Skip to main content
NVDA+0.17%AAPL+1.92%GOOGL+1.84%MSFT+0.81%AMZN+2.02%TSM+1.15%SPCX+1.89%AVGO+0.30%META+0.57%TSLA+0.60%SKHY+0.94%MU-0.08%BRK-B+0.56%LLY-0.74%JPM+0.82%WMT+1.33%AMD+2.45%V+0.99%XOM+0.19%ASMLa+0.26%JNJ-0.15%INTC+2.55%MA+0.87%0700.HK+0.66%1398.HK0.00%ABBV+0.64%BAC+0.12%CSCO+4.21%ORCL-1.98%CVX+0.52%COST+0.35%KO+0.53%CAT+1.69%LRCX-0.11%DELL+11.62%AP2d+1.32%AMAT+0.42%HSBA.L+1.31%0005.HK-0.85%PG+1.39%UNH-2.36%MS+0.74%GE-0.14%3988.HK+1.34%1816.HK+0.46%NFLX+1.82%0857.HK-1.09%HD+1.04%GS+0.86%PM+0.93%NZDJPY-2.73%CHFJPY-2.46%AUDJPY-2.05%CADJPY-1.85%EURJPY-1.78%USDJPY-1.63%GBPJPY-1.55%GBPNZD+1.20%NZDUSD-1.14%EURNZD+0.99%GBPCHF+0.92%NZDCAD-0.90%USDCHF+0.86%AUDNZD+0.72%EURCHF+0.69%NOKJPY-0.63%CADCHF+0.61%PLNJPY-0.56%USDTHB+0.53%EURZAR-0.50%GBPAUD+0.48%CHFSGD-0.46%SGDJPY-0.45%AUDCHF+0.43%AUDUSD-0.42%GBPTRY+0.41%USDZAR-0.38%AUDNOK+0.37%AUDDKK+0.35%USDTRY+0.32%GBPHKD+0.32%NZDCHF-0.30%GBPCAD+0.29%GBPMXN-0.28%CHFNOK-0.28%EURAUD+0.27%NZDSGD+0.27%GBPZAR-0.26%USDCAD+0.23%CHFSEK-0.23%AUDCAD-0.22%EURCNH-0.22%EURGBP-0.22%USDSEK+0.19%AUDSGD+0.19%EURSGD-0.18%NZDMXN+0.17%USDILS+0.16%EURUSD-0.16%USDNOK+0.14%USDDKK+0.12%EURHKD-0.12%USDMXN-0.12%USDPLN+0.09%GBPUSD+0.08%GBPSGD+0.08%EURCAD+0.07%EURSEK+0.07%EURPLN-0.05%USDSGD-0.04%USDCOP-0.04%USDHKD+0.02%USDCNH+0.02%EURNOK+0.01%EURCZK-0.01%EURDKK-0.01%UKOIL-3.88%USOIL-3.37%GAGUSD+1.16%XAGUSD+1.16%XPTUSD+0.93%XAUUSD+0.66%GAUUSD+0.66%HG1+0.31%XNGUSD-0.09%SUGAR0.00%COCOA0.00%W10.00%BTCUSD+1.01%ETHUSD+4.20%USDTUSD+0.02%XRPUSD+1.99%SOLUSD+3.38%TRXUSDT-0.90%ZECUSDT+9.19%DOGEUSD+1.95%XMRUSDT+2.15%LINKUSD+1.11%XLMUSD+2.37%BCHUSDT+2.00%LTCUSD+2.65%UNIUSD+2.09%TONUSD+27.68%HBARUSDT-0.46%SUIUSD-0.05%TAOUSDT+0.48%AAVEUSD+3.13%DOTUSDT-4.63%ICPUSDT-1.88%ONDOUSDT+2.92%WLDUSDT+1.26%ARBUSDT+1.43%ATOMUSDT-7.78%JUPUSDT+7.70%INJUSDT-0.95%STXUSDT+0.08%FETUSDT+3.28%TIAUSDT-2.66%PYTHUSDT-0.12%SEIUSDT+0.56%IMXUSDT+1.66%WIFUSDT+0.21%GRTUSDT-0.02%OPUSDT+1.78%POLUSDT+4.26%IOTAUSDT-0.57%AXSUSDT+2.63%FARTCOINUSDT+2.99%EOSUSDT-1.21%DYDXUSDT+1.79%ORDIUSDT-0.02%GALAUSDT+0.30%NOTUSDT+3.12%RONINUSDT+1.10%NVDA+0.17%AAPL+1.92%GOOGL+1.84%MSFT+0.81%AMZN+2.02%TSM+1.15%SPCX+1.89%AVGO+0.30%META+0.57%TSLA+0.60%SKHY+0.94%MU-0.08%BRK-B+0.56%LLY-0.74%JPM+0.82%WMT+1.33%AMD+2.45%V+0.99%XOM+0.19%ASMLa+0.26%JNJ-0.15%INTC+2.55%MA+0.87%0700.HK+0.66%1398.HK0.00%ABBV+0.64%BAC+0.12%CSCO+4.21%ORCL-1.98%CVX+0.52%COST+0.35%KO+0.53%CAT+1.69%LRCX-0.11%DELL+11.62%AP2d+1.32%AMAT+0.42%HSBA.L+1.31%0005.HK-0.85%PG+1.39%UNH-2.36%MS+0.74%GE-0.14%3988.HK+1.34%1816.HK+0.46%NFLX+1.82%0857.HK-1.09%HD+1.04%GS+0.86%PM+0.93%NZDJPY-2.73%CHFJPY-2.46%AUDJPY-2.05%CADJPY-1.85%EURJPY-1.78%USDJPY-1.63%GBPJPY-1.55%GBPNZD+1.20%NZDUSD-1.14%EURNZD+0.99%GBPCHF+0.92%NZDCAD-0.90%USDCHF+0.86%AUDNZD+0.72%EURCHF+0.69%NOKJPY-0.63%CADCHF+0.61%PLNJPY-0.56%USDTHB+0.53%EURZAR-0.50%GBPAUD+0.48%CHFSGD-0.46%SGDJPY-0.45%AUDCHF+0.43%AUDUSD-0.42%GBPTRY+0.41%USDZAR-0.38%AUDNOK+0.37%AUDDKK+0.35%USDTRY+0.32%GBPHKD+0.32%NZDCHF-0.30%GBPCAD+0.29%GBPMXN-0.28%CHFNOK-0.28%EURAUD+0.27%NZDSGD+0.27%GBPZAR-0.26%USDCAD+0.23%CHFSEK-0.23%AUDCAD-0.22%EURCNH-0.22%EURGBP-0.22%USDSEK+0.19%AUDSGD+0.19%EURSGD-0.18%NZDMXN+0.17%USDILS+0.16%EURUSD-0.16%USDNOK+0.14%USDDKK+0.12%EURHKD-0.12%USDMXN-0.12%USDPLN+0.09%GBPUSD+0.08%GBPSGD+0.08%EURCAD+0.07%EURSEK+0.07%EURPLN-0.05%USDSGD-0.04%USDCOP-0.04%USDHKD+0.02%USDCNH+0.02%EURNOK+0.01%EURCZK-0.01%EURDKK-0.01%UKOIL-3.88%USOIL-3.37%GAGUSD+1.16%XAGUSD+1.16%XPTUSD+0.93%XAUUSD+0.66%GAUUSD+0.66%HG1+0.31%XNGUSD-0.09%SUGAR0.00%COCOA0.00%W10.00%BTCUSD+1.01%ETHUSD+4.20%USDTUSD+0.02%XRPUSD+1.99%SOLUSD+3.38%TRXUSDT-0.90%ZECUSDT+9.19%DOGEUSD+1.95%XMRUSDT+2.15%LINKUSD+1.11%XLMUSD+2.37%BCHUSDT+2.00%LTCUSD+2.65%UNIUSD+2.09%TONUSD+27.68%HBARUSDT-0.46%SUIUSD-0.05%TAOUSDT+0.48%AAVEUSD+3.13%DOTUSDT-4.63%ICPUSDT-1.88%ONDOUSDT+2.92%WLDUSDT+1.26%ARBUSDT+1.43%ATOMUSDT-7.78%JUPUSDT+7.70%INJUSDT-0.95%STXUSDT+0.08%FETUSDT+3.28%TIAUSDT-2.66%PYTHUSDT-0.12%SEIUSDT+0.56%IMXUSDT+1.66%WIFUSDT+0.21%GRTUSDT-0.02%OPUSDT+1.78%POLUSDT+4.26%IOTAUSDT-0.57%AXSUSDT+2.63%FARTCOINUSDT+2.99%EOSUSDT-1.21%DYDXUSDT+1.79%ORDIUSDT-0.02%GALAUSDT+0.30%NOTUSDT+3.12%RONINUSDT+1.10%
OT

Oruka Therapeutics, Inc. (ORKA)

NASDAQ • Healthcare

$92.38
+$0.72 (+0.8%)
Market closed

Last close at September 11, 2026 at 20:00 UTC

Open$90.21
Day Range$88.07 - $92.29
Avg. Volume (3M)787.4K
Market Cap$5.4B
52 Week Range
$14.67$115.52
Next EarningsIn 61 daysNov 11, 2026

Metrics Over Time

Fundamentals & Financials

Revenue (TTM)
$0
Net Income (TTM)
-$132.8M
EPS (TTM)
-$2.47
ROA (TTM)
-11.66%
Current Ratio
38.51
Dividend Yield
0%

TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.

Earnings

+26.2%Q1 2026-$0.45
+12.2%Q2 2026-$0.48
-7.3%Q3 2026-$0.55
Next

Nov 11

in 61 daysQ4 2026

% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS

Latest report — Q3 2026
Miss -7.3%

Oruka Therapeutics’ preliminary results for the second fiscal quarter of 2026 showed adjusted EPS of -$0.55, which trailed the -$0.51 estimate (-7%), when it reported on August 10, 2026. On a year-over-year basis, adjusted EPS was down -19.6% from -$0.46 a year ago, alongside a GAAP net loss of roughly $41.2 million, down -67.7% from roughly $24.6 million in the prior-year period. The company also posted GAAP operating income of around -$50.1 million for the quarter, and it reported negative operating cash flow of about $33.1 million. For the next period, consensus calls for EPS of -$0.59.

View full earnings history

About Oruka Therapeutics, Inc.

Oruka Therapeutics, Inc. is a NASDAQ-listed biotechnology company in the healthcare sector that develops monoclonal antibody medicines for psoriasis and other inflammatory and immunology conditions. In qualitative terms, it is a clinical-stage business built around a small pipeline of named antibody programs rather than a marketed-product portfolio.

Name
Oruka Therapeutics, Inc.
CEO
Lawrence Otto Klein
Website
www.orukatx.com
Industry
Healthcare
Employees
68

Today's Snapshot

AI-generated

ORKA is trading 1.3% above yesterday's close, while its sector was flat.

Trading Volume

Below 10d avg (678.6K)

357.4K

vs S&P 500 Today

Moderate Outperformance

+0.31%

Updated: September 11, 2026 at 19:15 UTC

Technical Indicators

2 Buy2 Neutral4 Sell
ORKA shows a cautious sell bias as short-term momentum and trend signals are tepid while medium-term moving averages sit above the current price. Momentum measures including MACD and a negative ten-period momentum read as sellers, and the RSI sits below neutral rather than oversold, suggesting limited bullish conviction. Trend strength is moderate with ADX around the low-20s, and volume-based OBV is weak, which undercuts upside follow-through even though price trades near the VWAP. Volatility is elevated by ATR, implying wider intraday swings. Technical takeaway: Sell.
All signals
  • EMA (5 indicators)$63.18 - $95.69
    Sell
  • RSI (14)43.16
    Neutral
  • Stochastic %K (14, 3, 3)25.74
    Neutral
  • MACD Level (12, 26)-1.71
    Sell

Peers & Related Assets

NRIXNurix Therapeutics, Inc.
$25.1-2.8%
RAPPRapport Therapeutics, Inc. Common Stock
$43.62+0.4%
URGNUroGen Pharma Ltd.
$42.31+0.2%
KODKodiak Sciences Inc.
$32.88+0.0%
XNCRXencor, Inc.
$24.42+0.7%
ANABAnaptysBio, Inc.
$53.87-2.3%
Stay Ahead of the Market

Get premium market insights delivered directly to your inbox.